- 'Sleeper agent' bots on X fuel US election misinformation, study says
- Death toll rises to 109 after Haiti gang attack, official says
- Tigers beat Guardians and on brink of advancing in MLB playoffs
- Argentina MPs back Milei's veto of university funding
- Man City sink Barca in Women's Champions League as Bayern outgun Arsenal
- Greek international Baldock, 31, found dead in pool: state agency
- Florida seaside haven a ghost town as hurricane nears
- Pharrell Williams to co-chair Met Gala exploring Black dandyism
- Wall Street indices hit fresh records as Chinese shares tumble
- Taiwan's president to deliver key speech for National Day
- Sea row on the menu as ASEAN leaders meet China's Li
- Injured Kane won't start England's Nations League clash with Greece
- Discord seen as online home for renegades
- US forecasts severe solar storm starting Thursday
- Mozambique starts tallying votes in tense election
- Zelensky moves to court European leaders in drive for military aid
- Ratan Tata: Indian mogul who built a global powerhouse
- Rodgers rejects 'false' suggestions of role in Saleh dismissal
- One dead as storm Kirk tears through Spain, Portugal, France
- Indian business titan Ratan Tata dead at 86
- Lebanon facing 'catastrophic' situation as 600,000 displaced: UN
- US warns Israel not to repeat Gaza destruction in Lebanon
- Musk's X returns in Brazil after 40-day showdown with judge
- Call her savvy? Harris unleashes unconventional media blitz
- Lucian Freud 'masterpiece' fetches £13.9 million at London sale
- SoFi Stadium to hold next two CONCACAF Nations League finals
- McIlroy and DeChambeau set for PGA-LIV 'Showdown' in Vegas
- Fed minutes highlight divisions over rate cut decision
- Steve McQueen debuts new WWII film at London festival
- Run blitz edges India and South Africa closer to World Cup semi-finals
- Zelensky to court European leaders in drive for military aid
- Israel captain says 'difficult' to focus on football in time of war
- Macron to host Ukraine's Zelensky after meeting Ukrainian troops
- Root says 'many more to get' after England Test runs landmark
- India pile up World Cup high to rout Sri Lanka
- One year later, Israeli hostage family learns of loss
- Texans receiver Collins, Pats' safety Peppers out for NFL clash
- Biden-Netanyahu talk as Hezbollah, Israeli forces clash
- Musk's X available again in Brazil after 40-day ban
- Reddy stars as India crush Bangladesh to clinch T20 series
- Nobel winners hope protein work will spur 'incredible' breakthroughs
- What are proteins again? Nobel-winning chemistry explained
- Arch rivals Ghana, Nigeria drawn together in CHAN qualifying
- AI steps into science limelight with Nobel wins
- Trump lauds India's Modi as 'total killer'
- Wall Street, Europe rise as Chinese shares tumble
- Hunkering down for Hurricane Milton at Disney -- but first, a few rides
- Reddy, Rinku power India to 221-9 in second Bangladesh T20
- Overshooting 1.5C risks 'irreversible' climate impact: study
- Time running out in Florida to flee Hurricane Milton
UN urges Gilead to 'make history' with game-changing HIV drug
Gilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP.
Winnie Byanyima urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat HIV patients.
She urged Gilead to open up Lenacapavir to the UN-backed Medicines Patent Pool international organisation, whereby cheaper generic versions could be sold under licence in low- and middle-income nations.
Whatever the financial rewards of creating Lenacapavir, the renown of being the company that conquered the AIDS pandemic would be greater, Byanyima said.
"Gilead has an opportunity to take us closer to ending AIDS as a public health threat," Byanyima told AFP in an interview at UNAIDS' headquarters in Geneva.
"Gilead has an opportunity to save the world. To save the world, literally," from the pandemic.
"They can be the company that wins a Nobel Prize, for example. Reward doesn't come just through money. There is also recognition... imagine how great it would be."
- In a different league -
While around 10 million people with HIV still need to be reached with antiretroviral therapy, around 30 million are on such treatment.
Byanyima, the executive director of the Joint United Nations Programme on HIV and AIDS, said this was only possible thanks to innovations from pharmaceutical companies like Gilead.
But Lenacapavir is "so highly effective, it's in a different category of preventive medicines", she said.
Byanyima said the drug would help the hardest to reach.
"Those people hiding from the law -- gay men, trans women -- who could come out just twice a year to get their injection and be safe", she said, not to mention young women in Africa, fearing stigma and domestic violence.
Lenacapavir was approved for use for HIV patients in the United States and the European Union in 2022. It is available from around $40,000 a year in the US.
It is also being tested for potential pre-exposure prophylaxis (PrEP) use, to prevent people without HIV from getting the virus -- with very promising interim results.
Byanyima insisted that through tiered pricing -- for example someone in Nepal paying a fraction of the price of someone in Britain -- Gilead could still turn a profit on Lenacapavir.
"We could come close to ending this disease," she insisted.
Gilead has previously said it is in talks with governments and organisations "as we work to reach our access goals".
- 2030 target -
Broadly speaking, HIV innovations were producing better products for prevention and treatment with greater efficacy and fewer side effects, Byanyima said.
However, "a vaccine is very, very difficult to make. Same as a cure.
"But we have everything in between now for people to live long, healthy lives."
Some 1.3 million people were newly infected with HIV last year.
UNAIDS maintains it is possible to end HIV as a public health threat by 2030 -- but only if leaders make the right decisions on funding, resourcing and rights.
"We do see countries making progress towards that, which also proves that it is possible," said Byanyima.
She said that since 2010, some countries in sub-Saharan Africa had reduced new infections by more than half, and deaths by up to 60 percent.
However, "we also have regions such as Eastern Europe, Central Asia and Latin America where we see new infections moving in the wrong direction and rising," with stigma pushing people away from services.
- 'Fulfil the promise' -
Byanyima also warned of a "well-coordinated, well-resourced pushback" against LGBTQ rights, reproductive rights and gender equality.
She cited the harsher Anti-Homosexuality Act imposed in her native Uganda, moves to decriminalise female genital mutilation in The Gambia and the US Supreme Court stripping constitutional protections for abortion.
The 25th International AIDS Conference takes place in Munich from Monday to Friday, bringing together governments, civil society, academia, scientists and people living with HIV to share knowledge.
Byanyima said she wanted to see a boost in the political will to conquer the AIDS pandemic.
"Fulfil the promise that this disease will end. No-one should suffer, living with HIV," she said.
"We have all the possibilities for people to live healthy lives. And we should do it."
O.Johnson--AMWN